Company has addressed final review items from penetration testing and finalized cybersecurity and software documentation510(k) package submission ...

The precision testing, conducted following the Company's clinical cut-off adjustment, confirmed that the Intelligent Fingerprinting Drug Screening System produced consistent, reliable results across ...

Intelligent Bio Solutions forecasts a 32.6% profit increase, driven by higher-margin cartridge sales and market expansion efforts. Intelligent Bio Solutions Inc. announced preliminary unaudited ...

NEW YORK, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing ...

NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“Intelligent Bio Solutions” or the “Company”), a medical technology company delivering intelligent, rapid, ...

Detailed price information for Intelligent Bio Solutions Inc (INBS-Q) from The Globe and Mail including charting and trades.

Intelligent Bio Solutions Inc. (NASDAQ:INBS) on Tuesday reported a third quarter 2025 loss of 44 cents per share, down from a loss of $1.43 a year ago. The noninvasive testing solutions provider ...

Detailed price information for Intelligent Bio Solutions Inc (INBS-Q) from The Globe and Mail including charting and trades.

NEW YORK, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, ...

On Thursday, Intelligent Bio Solutions Inc. (NASDAQ:INBS) announced preliminary fiscal second-quarter sales of approximately $0.61 million and six-month sales of roughly $1.48 million. Gross profit is ...